Does Modulating the Gut Hormones, Incretins, Modify Vascular Function, Thereby Reducing the Risk of Vascular Complications in Insulin Resistant Individuals?

Trial Profile

Does Modulating the Gut Hormones, Incretins, Modify Vascular Function, Thereby Reducing the Risk of Vascular Complications in Insulin Resistant Individuals?

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Insulin resistance
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Apr 2017 Status changed from recruiting to completed.
    • 17 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top